ArticleBMC nephrology2025
Prevalence of undiagnosed stage 3 chronic kidney disease in the Tabari Cohort: a population-based study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) is a well-established public health concern worldwide. Considering the asymptomatic nature of early-stage CKD and its importance, we aimed to investigate the prevalence of undiagnosed stage 3 CKD in a large-scale, population-based cohort study.
methodsIn this cross-sectional study, data collected during the enrollment phase of the Tabari Cohort Study (TCS) were utilized. Between June 2015 and November 2017, 10,255 men and women aged 35-70 years were enrolled. CKD was determined based on the estimated glomerular filtration rate (eGFR). The Modification of Diet in Renal Disease (MDRD) equation, utilizing serum creatinine, was used to calculate eGFR. In the present study, participants with 30 ≤ GFR < 60 mL/min/1.73 m² were considered to have stage 3 CKD, and undiagnosed stage 3 CKD was defined as those unaware of CKD at enrollment but had an eGFR between 30 and 60 mL/min/1.73 m². Chi-square tests and univariate and multivariate logistic regression analyses were used to analyze the data.
resultsOut of 10,255 TCS participants, 25.6% (N = 2,630) had stage 3 CKD (30 ≤ eGFR < 60 mL/min/1.73 m²), with 98.1% (N = 2,579) being unaware of their disease. Multivariate logistic regression results showed that the risk of undiagnosed stage 3 CKD was significantly lower in mountainous residents (OR: 0.30, 95% CI: 0.13-0.73, P = 0.008) and participants with hypertension (OR: 0.35, 95% CI: 0.18-0.66, P = 0.001), diabetes (OR: 0.52, 95% CI: 0.29-0.95, P = 0.032), and cardiovascular disease (OR: 0.44, 95% CI: 0.23-0.82, P = 0.010) compared to urban residents and those without hypertension, diabetes, and cardiovascular diseases, respectively.
conclusionThe present study demonstrated a substantially high prevalence of undiagnosed stage 3 CKD. Urban residency and the absence of medical history of hypertension, diabetes, or cardiovascular disease were predictive factors of undiagnosed stage 3 CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.